Varberg Hospital
Welcome,         Profile    Billing    Logout  
 8 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jyrkkiö, Sirkku
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
Segelmark, MÃ¥rten
GOOD-IDES-02, NCT05679401: A Study With Imlifidase in Anti-GBM Disease

Active, not recruiting
3
50
Europe, US, RoW
Imlifidase, IdeS, HMED-IdeS, Plasma exchange (PLEX), PE, Cyclophosphamide (CYC), Glucocorticoids
Hansa Biopharma AB
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
06/25
11/26
Olsson, Mikael
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
Etzner, Mikael
WELBOW, NCT04173377: Elbow Outcomes Clinical Study

Completed
N/A
310
Europe, Canada
Stryker Trauma and Extremities
Orthopedic Disorder
09/24
09/24
Simonsen, Carl
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
Simonson, Carl
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
Rorsman, Cecilia
No trials found
Verstraaten, Maaike
No trials found

Download Options